澳大利亚原住民儿童中23价肺炎球菌多糖疫苗对肺炎住院的增量效果:一项记录链接研究
研究纳入2001至2012年出生于西澳大利亚、12月龄前完成3剂7价肺炎球菌结合疫苗的原住民儿童,随访18至60月龄,采用Cox回归估计18至30月龄接种PPV23对肺炎住院的风险比。结果显示PPV23对全因肺炎住院无统计学显著减少(HR 1.11;95%CI:0.87-1.43),推测肺炎球菌性肺炎(HR 0.47;95%CI:0.16-1.35)与其他明确病因(HR 0.89;95%CI:0.49-1.62)方向与未明确病因(HR 1.13;95%CI:0.86-1.49)不同。作者认为需更大规模、更好控制混杂的研究进一步指导PPV23接种。
要点
- PPV23对全因肺炎住院无统计学显著减少(HR 1.11;95%CI:0.87-1.43)。
- 推测肺炎球菌性肺炎HR 0.47(95%CI:0.16-1.35),未达统计学显著。
- 作者认为需更大规模、更好控制混杂的研究进一步指导PPV23接种。
核心结论
- 在该高风险人群中,18至30月龄接种PPV23加强剂对住院全因肺炎或推测肺炎球菌性肺炎这一更特异结局均未观察到统计学显著的增量效果。
- 作者认为接种指征混杂可能解释全因肺炎风险轻度升高的趋势。
- 作者认为需更大规模、更好控制混杂的研究进一步指导PPV23接种。
研究设计与样本
- 研究为记录链接研究,纳入2001至2012年出生于西澳大利亚、12月龄前完成3剂7价肺炎球菌结合疫苗的原住民儿童。
- 儿童从18至60月龄随访,观察首次肺炎住院(全因及3个亚组:推测肺炎球菌性、其他明确病因、未明确病因)。
- 采用Cox回归模型估计18至30月龄接种与未接种PPV23儿童肺炎住院的风险比,并调整混杂因素。
主要发现
- 11,120名儿童共发生327次全因肺炎住院首次事件,其中15次(4.6%)编码为推测肺炎球菌性,46次(14.1%)为其他明确病因,266次(81.3%)为未明确病因。
- PPV23对全因肺炎住院无统计学显著减少(HR 1.11;95%CI:0.87-1.43)。
- 推测肺炎球菌性肺炎HR 0.47(95%CI:0.16-1.35),其他明确病因HR 0.89(95%CI:0.49-1.62),未明确病因HR 1.13(95%CI:0.86-1.49),方向不一致。
- 在PPV23接种前基线期(12至18月龄),接种PPV23儿童的全因肺炎风险高于未接种儿童(RR:1.73;95%CI:1.30-2.28)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者认为接种指征混杂可能解释全因肺炎风险轻度升高的趋势。
- 作者认为需更大规模、更好控制混杂的研究进一步指导PPV23接种。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The impact of pneumococcal conjugate vaccines (PCVs) on pneumonia in children is well-documented but data on 23-valent pneumococcal polysaccharide vaccine (PPV23) are lacking. Between 2001 and 2011, Indigenous children in Western Australia (WA) were recommended to receive PPV23 at 18-24 months of age following 3 doses of 7-valent PCV. We evaluated the incremental effectiveness of PPV23 against pneumonia hospitalisation. METHODS: Indigenous children born in WA between 2001 and 2012 who received PCV dose 3 by 12 months of age were followed from 18 to 60 months of age for the first episode of pneumonia hospitalisation (all-cause and 3 subgroups: presumptive pneumococcal, other specified causes, and unspecified). We used Cox regression modelling to estimate hazard ratios (HRs) for pneumonia hospitalisation among children who had, versus had not, received PPV23 between 18 and 30 months of age after adjustment for confounders. RESULTS: 11,120 children had 327 first episodes of all-cause pneumonia hospitalisation, with 15 (4.6%) coded as presumptive pneumococcal, 46 (14.1%) as other specified causes and 266 (81.3%) unspecified. No statistically significant reduction in all-cause pneumonia was seen with PPV23 (HR 1.11; 95% CI: 0.87-1.43), but the direction of the association differed for presumptive pneumococcal (HR 0.47; 95% CI: 0.16-1.35) and specified (HR 0.89; 95% CI: 0.49-1.62) from unspecified causes (HR 1.13; 95% CI: 0.86-1.49). During the baseline period before PPV23 vaccination (12-18 months), all-cause pneumonia risk was higher among PPV23-vaccinated than unvaccinated children (RR: 1.73; 95% CI: 1.30-2.28). CONCLUSION: In this high-risk population, no statistically significant incremental effect of a PPV23 booster at 18-30 months was observed against hospitalised all-cause pneumonia or the more specific outcome of presumptive pneumococcal pneumonia. Confounding by indication may explain the slight trend towards an increased risk against all-cause pneumonia. Larger studies with better control of confounding are needed to further inform PPV23 vaccination.
引用
- Kabir A, Randall D, Newall AT, et al. Incremental effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia hospitalisation among Australian Indigenous children: A record linkage study. Vaccine. 2023. PMID: 37507273. doi:10.1016/j.vaccine.2023.07.042
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。